PT-141 and Bremelanotide: Understanding the Approved Use
VA Health & Wellness2 min read
In short
PT-141 is commonly used as a name for bremelanotide. Vyleesi is an approved bremelanotide product for selected premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is not labeled for sexual-performance enhancement or for men, and a compounded PT-141 vial should not be represented as Vyleesi.
On this page
Key takeaways
- What condition does the approval address?
The Vyleesi label describes acquired, generalized hypoactive sexual desire disorder, or HSDD, in premenopausal women.
- Why does a specific diagnosis matter?
Desire, arousal, discomfort, and concerns about sexual function may call for different evaluations.
- Which safety issues are especially important?
Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease.
- Does the approval cover a compounded vial?
No.
- What claims should be avoided?
Do not assume that approval for one population establishes general libido enhancement or treatment in another population.
- Prepare a private, informed discussion
Read our kisspeptin research guide to understand why different sexual-health peptides should be evaluated separately.
What condition does the approval address?
The Vyleesi label describes acquired, generalized hypoactive sexual desire disorder, or HSDD, in premenopausal women. The low desire causes marked distress or interpersonal difficulty and is not due to the excluded medical, psychiatric, relationship, medication, or substance causes described in the label. [S19] (opens in a new tab) This is more specific than a broad goal of “sexual wellness.” A clinician needs to assess whether the diagnosis and treatment context fit.
Why does a specific diagnosis matter?
Desire, arousal, discomfort, and concerns about sexual function may call for different evaluations. Tell the clinician what changed and why it is concerning to you. Bring relevant medications and medical history. Ask what factors should be assessed before choosing a treatment. A product promoted for intimacy does not automatically address every kind of sexual-health concern.
Which safety issues are especially important?
Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease. Its labeling addresses transient blood-pressure increases, nausea, focal hyperpigmentation, medication interactions, and pregnancy precautions. [S19] (opens in a new tab) This summary is not a complete screening tool. Your clinician should review the actual product's full labeling and your circumstances rather than relying on a short online list of possible effects.
Does the approval cover a compounded vial?
No. FDA explains that compounded drugs are not approved products. [S04] (opens in a new tab) A vial labeled PT-141 has its own formulation, source, and instructions. Do not assume it is interchangeable with Vyleesi's approved delivery system or use branded-product instructions for an unrelated preparation. Ask why the proposed product is being considered and whether an approved option can meet the medical need.
What claims should be avoided?
Do not assume that approval for one population establishes general libido enhancement or treatment in another population. Ask the clinician to identify which evidence supports the proposed use and which uncertainties remain. Results should be discussed in the context of symptoms and distress, not promised as a universal performance effect. A more precise conversation protects the clinical meaning of the approval.
Prepare a private, informed discussion
Read our kisspeptin research guide to understand why different sexual-health peptides should be evaluated separately. VA Health & Wellness's care overview can help prepare questions. This article is general education and does not establish your eligibility for bremelanotide or endorse compounded PT-141 for performance enhancement.
Frequently asked questions
Sources
[S19] DailyMed, NLM: VYLEESI prescribing information (opens in a new tab)
